Kuukausittainen tiedot osakepääomasta ja yhtiön äänivallasta

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) —

Listing market: Euronext Growth

ISIN -koodi: FR0010425595


Osakkeiden kokonaismäärä pääkaupungissa

Äänioikeuksien kokonaismäärä

12 / 31 / 2021



Tietoja Cellectisistä
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its…

Lue koko artikkeli täältä: